Leukemia Drugs Market Research Reports

From
From
Market Spotlight: Myelofibrosis - Product Thumbnail Image

Market Spotlight: Myelofibrosis

  • Report
  • 30 Pages
From
Drug analysis: Sprycel - Product Thumbnail Image

Drug analysis: Sprycel

  • Drug Pipelines
  • 23 Pages
From
Drug analysis: asciminib - Product Thumbnail Image

Drug analysis: asciminib

  • Drug Pipelines
  • 12 Pages
From
Drug analysis: Gleevec - Product Thumbnail Image

Drug analysis: Gleevec

  • Drug Pipelines
  • 29 Pages
From
Drug analysis: Bosulif - Product Thumbnail Image

Drug analysis: Bosulif

  • Drug Pipelines
  • 14 Pages
From
Drug analysis: Iclusig - Product Thumbnail Image

Drug analysis: Iclusig

  • Drug Pipelines
  • 25 Pages
From
Drug analysis: Tasigna - Product Thumbnail Image

Drug analysis: Tasigna

  • Drug Pipelines
  • 17 Pages
From
Drugs Analysis: Synribo - Product Thumbnail Image

Drugs Analysis: Synribo

  • Report
  • 12 Pages
From
From
From
BCMA Targeted Therapies, 2017-2030 - Product Thumbnail Image

BCMA Targeted Therapies, 2017-2030

  • Report
  • 143 Pages
From
From
From
Loading Indicator

On average over 40,000 are diagnosed with leukemia each year in the United States. It is also one of the most common cancers in children. Large differences in therapeutic outcomes exist among patient groups such as children and old age sufferers, and according to the form of a disease that has many variants such as Acute (AML) and Chronic (CML) Myelocytic Leukemia, Acute (ALL) and Chronic (CLL) Lymphocytic Leukemia, and Hairy Cell Leukemia (HCL). These variations have led to unmet needs among specific patient groups. The selection of expert and insightful reports in this section enable you explore these market opportunities by providing key industry data such as drug development strategies, international market trends and forecasts and profiles of major players like Novartis, Pfizer and Bristol-Myers Squibb. Show Less Read more

adroll